Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb;15(2):353-360.
doi: 10.1111/cts.13151. Epub 2021 Oct 2.

Effects of sevelamer carbonate versus calcium acetate on vascular calcification, inflammation, and endothelial dysfunction in chronic kidney disease

Darius L Mason  1   2 , Kavitha Godugu  3 , Daryl Nnani  4 , Shaker A Mousa  3
Affiliations

Effects of sevelamer carbonate versus calcium acetate on vascular calcification, inflammation, and endothelial dysfunction in chronic kidney disease

Darius L Mason et al. Clin Transl Sci. 2022 Feb.

Abstract

Hyperphosphatemia is present in most patients with end-stage renal disease (ESRD) and has been associated with increased cardiovascular mortality. Phosphate binders (calcium-based and calcium free) are the mainstay pharmacologic treatment to lower phosphorus levels in patients with ESRD. We evaluated biochemical markers of vascular calcification, inflammation, and endothelial dysfunction in patients with chronic kidney disease (CKD) treated with sevelamer carbonate (SC) versus calcium acetate (CA). Fifty patients with CKD (stages 3 and 4) were enrolled and assigned to treatment with SC and CA for 12 weeks. At the end of the study the biomarkers of vascular calcification, inflammation, and endothelial dysfunction were analyzed. A significant increase in HDL-cholesterol was observed with SC but not with CA in patients with CKD. Treatment with SC reduced serum phosphate, calcium phosphate, and FGF-23 levels and there was no change with CA treatment. The inflammatory markers IL-8, IFN-γ, and TNFα decreased with response to both treatments. The levels of IL-6 significantly increased with CA treatment and no change was observed in the SC treatment group. SC showed favorable effects on anti-inflammatory and vascular calcification biomarkers compared to CA treatment in patients with CKD stages 3 and 4 with normal phosphorous values.

Trial registration: ClinicalTrials.gov NCT01277497.

PubMed Disclaimer

Conflict of interest statement

Authors declared no competing interests for this work.

Figures

FIGURE 1
FIGURE 1
The flow chart of study design and procedure. SA, sevelamer carbonate; CA, calcium acetate
FIGURE 2
FIGURE 2
Changes in serum lipids after 12 weeks of treatment with sevelamer carbonate and calcium acetate. (a) Total cholesterol (TC), (b) high‐density‐lipoprotein cholesterol (HDL‐C), (c) triglycerides (TG), (d) low‐density lipoprotein cholesterol (LDL‐C). Mean ± SD *p < 0.05, ***p < 0.001
FIGURE 3
FIGURE 3
Changes in serum inflammatory markers after 12 weeks of treatment with sevelamer carbonate and calcium acetate. (a) Interleukin‐6, (b) Interleukin‐8, (c) Interleukin‐10, (d) IFN‐γ, (e) TNF‐α. Values expressed as mean ± SD **p < 0.01, ***p < 0.001
FIGURE 4
FIGURE 4
(a) ICAM‐1, (b) VCAM‐1, (c) P‐selectin, (d) E‐selectin, (e) L‐selectin. Values expressed as mean ± SD *p < 0.05, **p < 0.01
See this image and copyright information in PMC

References

    1. Viegas C, Araújo N, Marreiros C, Simes D. The interplay between mineral metabolism, vascular calcification and inflammation in chronic kidney disease (CKD): challenging old concepts with new facts. Aging (Albany NY). 2019;11:4274‐4299. - PMC - PubMed
    1. Lee SJ, Lee I‐K, Jeon J‐H. Vascular calcification—new insights into its mechanism. Int J Mol Sci. 2020;21:2685. - PMC - PubMed
    1. Vahed SZ, Mostafavi S, Khatibi SMH, Shoja MM, Ardalan M. Vascular calcification: an important understanding in nephrology. Vasc Health Risk Manag. 2020;16:167‐180. - PMC - PubMed
    1. Affret A, Wagner S, El Fatouhi D, et al. Validity and reproducibility of a short food frequency questionnaire among patients with chronic kidney disease. BMC Nephrol. 2017;18:297. - PMC - PubMed
    1. Ketteler M, Block GA, Evenepoel P, et al. Diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder: synopsis of the kidney disease: improving global outcomes 2017 clinical practice guideline update. Amm Intern Med. 2018;168:422‐430. - PubMed

Publication types

MeSH terms

Associated data

Grants and funding